Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Finrozole (MPV 2213ad) is a novel selective aromatase inhibitor that is partially reversible for breast development.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 130.00 | |
5 mg | In stock | $ 320.00 | |
10 mg | In stock | $ 480.00 | |
25 mg | In stock | $ 786.00 | |
50 mg | In stock | $ 1,080.00 | |
100 mg | In stock | $ 1,480.00 | |
500 mg | In stock | $ 2,960.00 |
Description | Finrozole (MPV 2213ad) is a novel selective aromatase inhibitor that is partially reversible for breast development. |
In vivo | To investigate the pharmacokinetics of finrozole (MPV-2213ad), a novel competitive aromatase enzyme inhibitor, in healthy male volunteers. METHODS: The study was an open, partly randomized cross-over study including 23 volunteers receiving single doses of 3, 9 mg, or 30 mg of finrozole as tablets or solution with 14 days between the administrations. The highest dose was given as tablets only. Serum concentrations of finrozole were determined using high performance liquid chromatography combined with mass spectrometry. RESULTS: The mean time to peak serum concentration ranged from 2.5 to 3.1, and 0.6-0.7 h after tablets and solution, respectively. The Cmax values increased as the dose increased. The calculated apparent mean elimination half-life (t(1/2,z)) was approximately 3 h after the solution, and approximately 8 h after the tablet. The AUC(0, infinity) after finrozole tablets increased proportionally from 3 mg to 9 mg and from 3 to 30 mg. The calculated relative mean bioavailabilities (AUC(0, infinity)-ratio) for the 3 mg and 9 mg doses of finrozole as tablets were 89% and 78%, respectively. CONCLUSIONS: The absorption of finrozole from the tablet formulation was relatively rapid, and the apparent elimination half-life was longer after the tablet than after the solution, probably reflecting the overlap of the absorption with the elimination phase.[1] |
Synonyms | MPV 2213ad, MPV-2213ad, MPV 2213, MPV-2213, MPV2213ad |
Molecular Weight | 322.34 |
Formula | C18H15FN4O |
CAS No. | 160146-17-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Finrozole 160146-17-8 Endocrinology/Hormones Aromatase MPV 2213ad MPV2213 MPV-2213ad MPV 2213 MPV-2213 MPV2213ad inhibitor inhibit